Coronavirus forcing Eli Lilly employees to work from home
March 9, 2020Sales and Marketing Chinese Coroanvirus, Eli Lilly, Eli Lilly Coronavirus, Wuhan Coronavirus, coronavirus
Eli Lilly is asking some of its employees to work from home to stop the spread of coronavirus on its …
Uganda finalising clinical trials on new injectable HIV drug
March 9, 2020Sales and Marketing AIDS, HIV, Uganda HIV, Uganda HIV/AIDS, uganda
Uganda is preparing to enter the final stages of developing a new HIV treatment to reduce stigma and discrimination of …
NICE shoots down Dupixent for severe asthma
March 9, 2020Sales and Marketing Dupixent, NHS, NICE, Regeneron, Sanofi, UK, asthma
NICE, the NHS’ drug watchdog in England and Wales, has announced its decision not to recommend Sanofi and Regeneron’s IL-4 …
Top Ten most popular articles on Pharmafile.com this week
March 6, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Chinese Coronavirus, Wuhan Coronavirus, china coronavirus, coronavirus, wuhan coronavirus.
The coronavirus continues to threaten the global drug supply line, with disruption to the US drug production pipeline from the …
Scorpion venom added to CAR-T therapy increases efficacy in brain cancer, research shows
March 6, 2020Medical Communications, Research and Development CAR-T, Cancer, brain cancer, glioblastoma, pharma
Chimeric antigen receptor T cell (CAR-T) therapy has gained much traction and attention in the past years for its innovative …
Lack of mental health treatment available for HIV patients in the UK
March 6, 2020Medical Communications AIDS, HIV, HIV AIDS, HIV treatment, HIV/AIDS
A cross-party group of MPs have said that those with HIV do not have access to adequate mental health treatment. …
Phase 3 failure for AstraZeneca’s Imfinzi combo in unresectable metastatic bladder cancer
March 6, 2020Medical Communications, Research and Development AstraZeneca, Cancer, Imfinzi, bladder cancer, pharma, trial failure
New Phase 3 has been released by AstraZeneca, showing that the PD-L1 inhibitor Imfinzi (durvalumab), when combined with tremelimumab, failed …
Indian regulators approve first drug for patients with NASH
March 6, 2020Medical Communications FDA Approval, India, Indian Pharma, drug approval
The Drug Controller General of India (DCGI) has approved the marketing application for Zydus Cadila’s saroglitazar to treat patients with …
New study calculates median drug development costs at circa $1 billion
March 5, 2020Manufacturing and Production, Research and Development, Sales and Marketing drug development, drug prices, pharma
New research has pinned a concrete figure on the perennial industry question: how much does it cost to bring a …
UK cases of coronavirus hit 90 as health officials move into next phase of their response
March 5, 2020Business Services Chinese Coronavirus, MERS, Sars, Wuhan Coronavirus, coronavirus
The coronavirus has continued to spread across the UK as health officials announce they have moved into the second stage …
China approves Roche’s Actemra to fight severe complications stemming from coronavirus
March 5, 2020Sales and Marketing Actemra, China, Roche, coronavirus, pharma
China has moved to authorise Roche’s Actemra (tocilizumab) as a treatment for severe complications from contracting the COVID-19 coronavirus in …
Researchers have tested CRISPR gene editing inside a person’s body for the first time
March 5, 2020Business Services Editas, crispr, gene editing
Allergan and Editas Medicine have treated their first patient in a clinical trial with CRISPR gene editing. This therapy is …
US prescription drug net costs rose three times faster than inflation from 2007 to 2018
March 5, 2020Business Services Big Pharma, Trump drug prices, US Drug prices, drug prices, us drugs
The nest cost of prescription drugs rose over three times faster than the rate of inflation over the course of …
Positive CHMP approval for Takeda’s Alunbrig in ALK+ advanced non-small lung cancer
March 4, 2020Research and Development CHMP, EMA, Takeda, lung cancer, pharma
Takeda’s Alunbrig (brigatinib) has been recommended for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human …
Big Pharma more profitable than most public firms
March 4, 2020Research and Development Big Pharma, US Pharma, drug prices, drug regulations, regulations
Large pharmaceutical companies make a much larger profit than most other public companies, according to a new study. The research …
India reducing API exports due to coronavirus threatening global supply chain
March 4, 2020Research and Development APIs, Active Pharmaceuticals Ingredients, Big Pharma, Chinese Coronavirus, Wuhan Coronavirus, coronavirus
India is set to reduce exports of active pharmaceutical ingredients (APIs) until further notice, due to fears of internal drug …
NICE recommends avatrombopag to treat thrombocytopenia in chronic liver disease
March 4, 2020Research and Development Avatrombopag, NHS, NICE, UK, chronic liver disease
UK drug watchdog NICE has announced its final draft guidance recommending avatrombopag for routine use on the NHS in England …
Trump meets pharmaceutical executives to discuss COVID-19 vaccine
March 4, 2020Research and Development COVID-19, Chinese Coronavirus, Trump, Wuhan Coronavirus, coronavirus
President Trump has met with several representatives of the top pharmaceutical companies to discuss progress being made on a coronavirus …
MSD’s Phase 3 study of lymphoma treatment meets primary endpoints
March 3, 2020Manufacturing and Production B-cell lymphoma, classical Hodgkin Lymphoma, lymphoma
MSD announced that its Phase 3 study of Keytruda (pembrolizumab) for the treatment of adults with relapsed or refractory classical …
Gilead acquires immuno-oncology firm Forty Seven in $4.9 billion deal
March 3, 2020Manufacturing and Production, Sales and Marketing Cancer, Forty Seven, Gilead, acquisition, oncology, pharma
Gilead has revealed it is to acquire the immunology firm Forty Seven in a deal valued at $95.50 per share …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
